Economics

Is Your Fundraising Strategy Really Diverse?

Best practices articel from onPhilanthropy asks the question: Is your donor base as diverse as the population you serve: Some quotes:

Read More »

California-China Connection: China Syndromes (2 or 2)

Having gushed effusively about Leroy Hood, I’d like to turn to the China part of the conference. First, through, one last note about Hood. He had three messages for the Chinese: Everything he’s ever done that was important (including current work) has been met with great resistance. It’s not too late to get in on the ground floor of systems ...

Read More »

Molecular Medicine: Send in the lawyers (3 of 3)

One of the most interesting aspects of this conference on molecular medicine was a couple of sessions about intellectual property (IP). IP is the mother’s milk of the life science industry. What they have that is really of value is what they know and know how to do. Those intangibles are the gold assets of the industry just as the ...

Read More »

Molecular Medicine: The Molecule Biz (2 of 3)

In the previous installment about the molecular medicine conference, I emphasized that the science of so-called complex, polygenic diseases like cancer is, well, complex. But there are other complications as well in the life science business. Biotechnology and pharmaceuticals are also risky, complicated enterprises from a financial standpoint. In a way it’s kind of a layering of complexities, one atop ...

Read More »